Not necessarily. A company with a drug already on a fast track, and demonstrably better than the current standard of care, may not see the necessity of using the PRV to save possibly a handful of months when a very large company had a far greater financial imperative to buy it.
KZA Price at posting:
98.5¢ Sentiment: Hold Disclosure: Held